UCB has announced that The Lancet published full results from EXXELERATE, the first head-to-head superiority study of two treatments in...
The National Institute for Health and Care Excellence is supporting use of Cimzia (certolizumab pegol), from UCB, alone, or in...
The purpose of the study is to demonstrate the efficacy and safety of certolizumab pegol in the treatment of moderate to severe chronic plaque psoriasis in study participants aged 6 to 11 and 12 to 17 years.
Patients with active Axial Spondyloarthritis without x-ray evidence of Ankylosing Spondylitis and with signs of inflammation will be randomly assigned to receive certolizumab pegol (CZP) 200 mg every two weeks or placebo.
Objective: Data were pooled from the ongoing trials to investigate efficacy in selected subgroups and add precision to estimates of treatment effects during the initial 16 weeks of treatment.
UCB has announced positive top-line results from the phase III study designed to evaluate the efficacy and safety of Cimzia...
In this second part of a three-part series on treating moderate-to-severe psoriasis, we focus on key considerations and available treatment options for women of childbearing age.
UCB and Dermira announced topline results from CIMPASI-2, a Phase III, multi-center, placebo-controlled clinical trial evaluating the efficacy and safety...
Dermira, Inc and UCB, announced that the first patients have been dosed in the Phase III clinical program designed to...
Cimzia (certolizumab pegol), from UCB, in combination with methotrexate, is recommended by the UK NICE (National Institute for Health and...